专利检索 ap:("ISIS PHARMACEUTICALS, INC.") AND inv:"ETO, Tatsuo" 第 1 页

1.

发明授权
COMPOSITIONS AND METHODS FOR TREATMENT OF HEPATITIS C VIRUS-ASSOCIATED DISEASES 失效
标题翻译：组合物和方法丙型肝炎病毒与相关的疾病

公开(公告)号：EP0662157B1

公开(公告)日：2001-06-20

申请号：EP93919644.0

申请日：1993-09-10

申请人： ISIS PHARMACEUTICALS, INC.

发明人： ANDERSON, Kevin, P. , HANECAK, Ronnie, C. , HOSHIKO, Kazuya , NOZAKI, Chikateru , NISHIHARA, Tsukasa , NAKATAKE, Hiroshi , HAMADA, Fukusaburo , ETO, Tatsuo , FURUKAWA, Shinichi

IPC分类号： C12Q1/70 , C12N15/11 , C07H21/00 , G01N33/576

CPC分类号： C12N15/1131 , C07H21/00 , C07K14/005 , C12N2310/315 , C12N2310/33 , C12N2310/3521 , C12N2310/3527 , C12N2770/24222 , C12Q1/707

摘要： Antisense oligonucleotides are provided which are complementary to at least a portion of HCV RNA and specifically hybridizable therewith. These oligonucleotides can be administered to inhibit the replication of Hepatitis C virus in vivo or in vitro and to treat Hepatitis C virus-associated disease. These compounds can be used either prophylactically or therapeutically to reduce the severity of diseases associated with Hepatitis C virus.

2.

发明公开
COMPOSITIONS AND METHODS FOR TREATMENT OF HEPATITIS C VIRUS-ASSOCIATED DISEASES 失效
标题翻译：组成和丙型肝炎的方法对病毒病的复合材料的处理。

公开(公告)号：EP0662157A1

公开(公告)日：1995-07-12

申请号：EP93919644.0

申请日：1993-09-10

申请人： MOCHIDA PHARMACEUTICAL CO., LTD. , JURIDICAL FOUNDATION THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE , ISIS PHARMACEUTICALS, INC.

发明人： ANDERSON, Kevin, P. , HANECAK, Ronnie, C. , HOSHIKO, Kazuya , NOZAKI, Chikateru , NISHIHARA, Tsukasa , NAKATAKE, Hiroshi , HAMADA, Fukusaburo , ETO, Tatsuo , FURUKAWA, Shinichi

IPC分类号： A61K31 , C12N15 , A61P31 , C07H21 , C07K14 , C12N5 , C12P21 , C12Q1 , G01N33

CPC分类号： C12N15/1131 , C07H21/00 , C07K14/005 , C12N2310/315 , C12N2310/33 , C12N2310/3521 , C12N2310/3527 , C12N2770/24222 , C12Q1/707

摘要： Antisense oligonucleotides are provided which are complementary to at least a portion of HCV RNA and specifically hybridizable therewith. These oligonucleotides can be administered to inhibit the replication of Hepatitis C virus in vivo or in vitro and to treat Hepatitis C virus-associated disease. These compounds can be used either prophylactically or therapeutically to reduce the severity of diseases associated with Hepatitis C virus.